| Literature DB >> 30421664 |
Arnold Tóth1,2,3, Zoltán Berente4,5,6, Péter Bogner2, Bálint Környei1, Bendegúz Balogh2, Endre Czeiter1,3,5, Krisztina Amrein1,5, Tamás Dóczi1,3,7, András Büki1,5, Attila Schwarcz1.
Abstract
Previously, we reported human traumatic brain injury cases demonstrating acute to subacute microbleed appearance changes in susceptibility-weighted imaging (SWI-magnetic resonance imaging [MRI]). This study aims to confirm and characterize such temporal microbleed appearance alterations in an experimental model. To elicit microbleed formation, brains of male Sprague Dawley rats were pierced in a depth of 4 mm, in a parasagittal position bilaterally using 159 μm and 474 μm needles, without the injection of autologous blood or any agent. Rats underwent 4.7 T MRI immediately, then at multiple time points until 125 h. Volumes of hypointensities consistent with microbleeds in SWI were measured using an intensity threshold-based approach. Microbleed volumes across time points were compared using repeated measures analysis of variance. Microbleeds were assessed by Prussian blue histology at different time points. Hypointensity volumes referring to microbleeds were significantly decreased (corrected p < 0.05) at 24 h compared with the immediate or the 125 h time points. By visual inspection, microbleeds were similarly detectable at the immediate and 125 h imaging but were decreased in extent or completely absent at 24 h or 48 h. Histology confirmed the presence of microbleeds at all time points and in all animals. This study confirmed a general temporary reduction in visibility of microbleeds in the acute phase in SWI. Such short-term appearance dynamics of microbleeds should be considered when using SWI as a diagnostic tool for microbleeds in traumatic brain injury and various diseases.Entities:
Keywords: MRI; brain trauma; microbleed; rat; susceptibility weighted imaging (SWI)
Year: 2019 PMID: 30421664 PMCID: PMC6531906 DOI: 10.1089/neu.2018.6004
Source DB: PubMed Journal: J Neurotrauma ISSN: 0897-7151 Impact factor: 5.269

Illustration of the applied regions of interests (ROIs, overlaid on an immediate time point minimal intensity projection image) and their histograms with dash-dot lined boxes indicating “hypointense voxel” range. (a, d) Normal brain ROI and histogram, used to define hypointensity: the average value of the lowest intensities over normal brain (including all animals' immediate time point images, not only the presented one) was found to be 76; therefore, voxels with an intensity of ≤75 were defined as hypointense. (b, e) Microbleed ROI and histogram, used to calculate the number of hypointense voxels at injury sites corresponding to microbleed volumes (applied at all time points). The presented microbleed ROI included 791 hypointense voxels (see box in histogram). (c, f) Control ROI and histogram, for calculating the hypointense voxel number (applied at all time points) of the hypointense structure parietal bone assumed not to undergo volume changes over time. The presented control ROI included 1,202 such hypointense voxels (see box in histogram).

(A) Coronal susceptibility-weighted imaging (SWI) minimum intensity projection images of three rats that underwent five imaging time points (each row represents different animals). Hypointensities along both the left and right side brain parenchymal injury sites were present in the immediate acquisition. The hypointensities became smaller or completely absent in the 12 h, 24 h, and 48 h acquisitions. In the 125 h acquisitions, the hypointensities were again present in a similar shape, extent, and intensity as at the immediate time point. In the second animal, at the larger gauge injury track (left), a relatively large circumscribed blood collection was formed showing no noticeable change over time. (B) Coronal maximum intensity projection images of the same rats' filtered phase images. Hyperintensities consistent with phase alteration at lesion sites are more pronounced at the immediate and 125 h imaging time point than at the 12 h, 24 h, or 48 h time points.

Coronal susceptibility-weighted imaging minimum intensity projection images of 10 rats that underwent three imaging time points (each column represents different animals). Hypointensities along both the left and right side brain parenchymal injury sites were present in the immediate acquisition. The hypointensities became smaller or completely absent at the 24 h time point and were again present at the 125 h time point, with a similar shape, extent, and intensity as at the immediate time point. In the first and ninth animals, at the larger gauge injury track (left), relatively large circumscribed blood collections were formed showing no noticeable change over time.

Average temporal susceptibility-weighted imaging hypointensity extent changes at the injury sites in 13 animals. (A) Left side (larger gauge injury). (B) right side (lesser gauge injury). Asterisks refer to analysis of variance pairwise comparisons between time points resulting in a Bonferroni corrected p value of <0.05.
Results of Hypointensity Extents Repeated Measures Analysis of Variance
| Extent[ | Immediate | 908 | 652 | 1958 |
| 24 h | 212 | 64 | 2134 | |
| 125 h | 716 | 578 | 2286 | |
| 24 h vs. Immediate | < 0.0001 | 0.0022 | 1 | |
| 24 h vs. 125 h | 0.0004 | 0.0048 | 1 | |
| Immediate vs. 125 h | 0.317 | 1 | 0.46 |
Number of hypointense voxels in the minimum intensity projection images.
p values from pairwise comparisons, Bonferroni corrected.

Correlations of susceptibility-weighted imaging (SWI) and histology of microbleeds. First, second, and third lines show rats that were euthanized after the immediate, 24 h, or 125 h imaging, respectively. The available coronal SWI minimum intensity projection images of microbleeds of interest are presented, with inserts indicating the corresponding histological (Prussian blue staining, 70x and 800x) images. Blood products are apparent in the animal euthanized at 24 h and 125 h as well, despite the absence of hypointensities in the 24 h SWIs. Prussian blue staining indicates the presence of hemosiderin at 125 h.